Please rotate your device to portrait orientation
30 JUNE 2017
IGEM Therapeutics have appointed Consultancy Thirteen to design and build a new web presence supporting their development of novel IgE antibodies ot treat cancer.
The company’s lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase 1/2a trial to treat ovarian cancer; the world’s first IgE therapeutic to enter the clinic.
IGEM is also developing a novel antibody platform technology based on protein and glyco-engineering of the epsilon constant region.
The site is due to go live in the late Autumn 2017.